| Name | Title | Contact Details |
|---|---|---|
Pankaj Daga |
Associate Director (CMC and Supply Chain) | Profile |
Jenny Klinger |
Head of Financial Planning and Analysis | Profile |
Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Quva is a national provider specializing in health-system pharmacy services, focusing on sterile injectable compounding and advanced data software platforms. The company operates FDA-registered 503B outsourcing facilities that manufacture ready-to-administer compounded sterile pharmaceuticals, serving thousands of hospitals across the United States. Quva adheres to stringent cGMP standards and utilizes automation and integrated technologies to ensure a reliable supply of high-quality medications. Quvas operations are divided into two main divisions. Quva Pharma delivers essential sterile compounded medications, addressing supply chain reliability and medication shortages. Quva BrightStream offers a data analytics platform that aggregates and analyzes healthcare data, providing actionable insights to optimize pharmacy operations. The company emphasizes patient safety, transparent customer service, and a commitment to innovation and quality, making it a trusted partner for health systems and hospital pharmacies.
Pionyr Immuntherapeutics (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body`s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company`s approach, Myeloid Tuning™, is designed to enhance the immune system`s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options and mechanisms of action. We are taking a fundamentally different approach to the way treatments for brain diseases are developed. Our pipeline is comprised of programs pursuing therapeutically relevant targets implicated in Central Nervous System (CNS) diseases, each targeting a novel mechanism of action with best-in-class pharmacology. Our work is supported by our Precision Toolbox, which integrates a suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora is relentless in its commitment to discovering, developing and commercializing novel therapies for the 1.5 billion people living with brain diseases.
Singular Genomics is pushing sequencing further to bring fast, powerful and flexible tools for research and medicine. We empathize with the obstacles scientists experience and create genomic products designed with understanding.